|
Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Located in Deerfield, Illinois, the company serves as the headquarters for the Americas and employs more than 2,300 people. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
Our commitment to changing tomorrow is measured not only by our focus on bringing innovative and effective new medicines to patients and physicians, but also by the importance we place on the impact we can make within the communities where we work and live. Astellas supports many causes and has created two initiatives to demonstrate our commitment: Changing Tomorrow Day, an annual, worldwide volunteer event, and Science WoRx, a nationwide mentoring program and online resource network for science teachers and their students.
Astellas Pharma US, Inc.
Three Parkway North
Deerfield, IL 60015-2548
Phone: 800-695-4321
President & CEO
Masao Yoshida
Americas Employees
2,429 (FY 2010)
Americas Product Sales:
$2.2 billion*
*Figures represent approximate U.S. dollar / yen exchange
rate of ¥86 / 1USD.
Include sales from the U.S. and Canada.
U.S. Marketed Pharmaceutical Products
Cardiology
Dermatology
Immunology
- Prograf® (tacrolimus capsules and injection)
Infectious Disease
- AmBisome® (amphotericin B) liposome for injection
- Mycamine® (micafungin sodium) for injection
- VIBATIV® (telavancin)
Neuroscience
Oncology
Urology
On January 6, 2012, Astellas Pharma Inc. and Theravance, Inc. announced that Astellas has exercised its right to terminate the global License, Development and Commercialization Agreement for VIBATIV® (telavancin) for injection. The rights granted to Astellas ceased upon termination of the Agreement and Astellas has stopped promotional sales efforts.
All trademarks are Astellas’ except:
AmBisome is a registered trademark of Gilead Sciences, Inc.
Sumavel and DosePro are trademarks of Zogenix, Inc.
Tarceva is a registered trademark of OSI Pharmaceuticals, LLC.
Major U.S. Pipeline Products
| Code No. / Generic Name |
Therapeutic Target |
Area / Phase |
| Mirabegron |
Overactive bladder |
Phase III |
| MDV3100 |
Prostate cancer |
Phase III |
| Isavuconazole |
Invasive aspergillosis |
Phase III |
| Candidemia / Invasive candidiasis |
Phase III |
| Erlotinib |
Hepatocellular carcinoma |
Phase III |
| OSI-906 |
Adrenocortical carcinoma |
Phase III |
| Tivozanib |
Renal cell carcinoma |
Phase III |
Major Corporate Highlights
April 2005—Established U.S. headquarters near Chicago, Illinois, with the merger of Yamanouchi & Fujisawa
March 2006—Established Urogenix, Inc. in Durham, North Carolina, expanding research capabilities in urology
November 2007—Acquired Agensys, Inc. in Santa Monica, California, which is the company’s center for therapeutic antibody research and development in cancer
March 2008—Established a new U.S.-based subsidiary, Astellas Pharma Global Development, Inc. in Deerfield, Illinois, which acts as the headquarters for global development
July 2009—Established Astellas Farma Brasil Importacao e Distribuicao de Medicamentos Ltda., in Sao Paulo, Brazil
April 2010—Began construction on new headquarters for the Americas in Glenview, Illinois
June 2010—Acquired OSI Pharmaceuticals, LLC in Farmingdale, New York, which is the center of the company’s small-molecule oncology research
January 2011—Began construction on new facility for Agensys in Santa Monica, California
May 2011—Acquired Perseid Therapeutics LLC in Redwood City, California, which focuses on the discovery, research, and development of multiple protein pharmaceutical programs
Corporate Recognition Awards
Chicago Tribune Top Workplace (2010)
Chicago’s 101 Best and Brightest
Companies to Work For (2009-Elite & 2010)
The Scientist – Best Places to Work in Industry (2010)
Workforce Chicago (2009)
|
